STOCK TITAN
  1. Home
  2. News
  3. WXXWY

Wuxi Biologics (Cayman) Inc. - WXXWY STOCK NEWS

Welcome to our dedicated news page for Wuxi Biologics (Cayman) (Ticker: WXXWY), a resource for investors and traders seeking the latest updates and insights on Wuxi Biologics (Cayman).

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Wuxi Biologics (Cayman)'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Wuxi Biologics (Cayman)'s position in the market.

News
WuXi Biologics Successfully Implemented a Fully Integrated Continuous Process with a Breakthrough Productivity of ~6 g/L/day at Pilot Scale
Rhea-AI Summary
WuXi Biologics (2269.HK) has completed its first end-to-end continuous drug substance (DS) manufacturing from perfused cell culture to final UF/DF pool at pilot scale. The company achieved an average daily productivity of 6 g/L/day for a mAb molecule during the 18-day production phase, leading to a significantly high accumulated volumetric productivity at 105 g/L in the 25-day continuous cell culture process. The total yield calculated from Protein A capture to UF/DF reached nearly 80%, delivering over 3 kg protein from 40 L working volume. WuXi Biologics' end-to-end continuous DS manufacturing enabled by WuXiUPTM allows a 1,000 L disposable bioreactor to produce more than 60 kg of mAb per batch and approximately 800 kg per year, achieving productivity comparable to a traditional 10,000-20,000L bioreactor. The company aims to expedite biologics development, reduce the cost of goods (COGS) of commercial products, and increase operational flexibility due to minimal facility footprint utilization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.43%
Tags
none
-
News
WuXi Biologics Receives AAA MSCI ESG Rating
Rhea-AI Summary
WuXi Biologics (2269.HK) has received an AAA rating from MSCI ESG Ratings, signaling outstanding performance in key ESG issues like climate change, corporate governance, talent development, and product safety & quality. This recognition solidifies WuXi Biologics' position as an industry leader in managing significant ESG opportunities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.96%
Tags
none
-
News
WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality
Rhea-AI Summary
WuXi Biologics launches WuXiUI™, a new proprietary bioprocessing platform that enhances productivity and reduces costs in biologics development and manufacture.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.39%
Tags
none
News
WuXi Biologics Congratulates Amicus Therapeutics on U.S. FDA Approval for New Treatment for Pompe Disease
Rhea-AI Summary
WuXi Biologics congratulates Amicus Therapeutics on FDA approval for Pombiliti™ and Opfolda™ for late-onset Pompe disease. WuXi Biologics is the exclusive manufacturing partner for the therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.29%
Tags
fda approval
-
News
WuXi Biologics Reports Solid 2023 Interim Results
Rhea-AI Summary
WuXi Biologics reports solid business performance with sustained growth momentum and strong backlog
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
none
-
News
WuXi Biologics and Boostimmune Sign MOU for Exclusive Research and Discovery Services
Rhea-AI Summary
WuXi Biologics and Boostimmune have signed a Memorandum of Understanding for research and discovery services. Boostimmune will have access to WuXi Biologics' integrated discovery services and expertise in antibody discovery. WuXi Biologics will be the exclusive service partner to support Boostimmune in generating different modality candidates.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
none
News
WuXi Biologics to Increase Manufacturing Capacity in Germany
Rhea-AI Summary
WuXi Biologics is expanding its manufacturing capacity in Germany in response to increasing demand for contract manufacturing services. The expansion includes the installation of a new drug product fill line at the Leverkusen site and a doubling of the biomanufacturing capacity at the Wuppertal site.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
none
-
News
WuXi Biologics Receives 2023 ISPE Facility of the Year Award for Operations
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.12%
Tags
none
-
News
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patients
Rhea-AI Summary
WuXi Biologics partners with InflaRx for manufacturing COVID-19 treatment Gohibic (vilobelimab)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.03%
Tags
partnership covid-19
News
WuXi Biologics Releases 2022 ESG Report Detailing Its Continued Commitment to Sustainability
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
none
Stock WXXWY logo
Wuxi Biologics (Cayman) Inc.

OTC:WXXWY

WXXWY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

WXXWY Stock Data

7.39B
3.62B
0.01%
Testing Laboratories
Professional, Scientific, and Technical Services
Link
China (Mainland)
No 108 Meiliang Road Mashan

About WXXWY

wuxi biologics provides an open-access, integrated technology platform for biologics drug development. we are the only true service platform in the world offering end-to-end solutions to empower anyone to discover, develop and manufacture biologics from concept to commercial manufacturing. our single-source approach to biologics development saves our clients critical time and money. see below how our experience, capacities and quality make us a world leading (cdmo). experience wuxi biologics’ leadership team consists of industry experts with 15-20 years of experience in biological drug development in the u.s./eu. while at wuxi this team has contributed to 1 bla and 66 worldwide inds in just 3 years! expertise wuxi biologics has over 170+ returnees from large pharma and small biotechs in the u.s./eu. these scientists cover all facets of drug development from discovery to manufacture of final drug product. capacity and capabilities we have strong technical capabilities and an open-access